All lobbying filings

MANATT, PHELPS, AND PHILLIPS

MANATT, PHELPS, AND PHILLIPS filed a Q1 report for DENALI THERAPEUTICS on April 15, 2025, reporting $67,500 in lobbying income.

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

All filings by MANATT, PHELPS, AND PHILLIPS · Everything DENALI THERAPEUTICS has reported

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Apr 15, 2025.

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 15, 2025

Income

$67,500

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbying activity 1

Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.